| About the author: |
O. M. Bilovol, I. I. Kniazkova, T. V. Frolova, N. V. Kuzminova, V. O. Barbashova, V. P. Starenkiy, M. V. Bohun |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
60 females (mean age 62.7±3.8 years) with arterial hypertension of stage II, degree 2, postmenopausal osteoporosis (according to the data of osteodensitometry) and not receiving regular antihypertensive therapy were examined. After baseline data registration hypertension therapy with a combination of lisinopril 10–20 mg and indapamide 2.5 mg per day was prescribed to 30 patients (group 1), and lisinopril 10–20 mg plus hydrochlorothiazide 12.5 mg per day for 12 weeks – to 30 patients (group 2). The control group consisted of 20 practically healthy females. All examined persons underwent clinical and laboratory examinations according to the protocols for the examination of patients with arterial hypertension and osteoporosis. Analysis of indicators after 12 weeks revealed the high antihypertensive efficacy of both treatment regimens. In patients with arterial hypertension and postmenopausal osteoporosis, according to the data of office measurement of blood pressure and daily monitoring of blood pressure, 12-week therapy with a combination of lisinopril and indapamide did not significantly differ from the therapy with lisinopril in combination with hydrochlorothiazide in terms of the severity of antihypertensive effect, an ability to normalize the daily profile of blood pressure and reduce pressure load indicators. Propagation velocity of pulse wave and central aortic pressure levels (cSBP and cPP) according to applanation tonometry significantly decreased more during 12-week therapy with lisinopril in combination with indapamide compared to the combination of lisinopril with hydrochlorothiazide, along with good tolerability in both treatment groups. |
| Tags |
hypertension,postmenopausal osteoporosis,central aortic pressure,arterial stiffness,indapamide |
| Bibliography |
- Zubach OB, Hryhoryeva NV. 10-richna letalnist u zhinok pislya perelomiv proksymalnoho viddilu stehnovoyi kistky. Bukovynskyy medychnyy visnyk. 2020; 24(3): 28–33. doi: 10.24061/2413-0737.XXIV.3.95.2020.67. [in Ukrainian]
- Ahn E, Lee J, Yong SP, Noh HM, Bo HK. Association between delivery at an advanced maternal age and osteoporosis in elderly Korean women. J Bone Miner Metab. 2015;33:666–73.
- Alon US. The Effects of Diuretics on Mineral and Bone Metabolism. Pediatr Endocrinol Rev. 2018;15(4):291-297.
- Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst. Rev. 2011;10:Cd005185. doi: 10.1002/14651858.CD005185.pub2.
- Chuang CH, Yang SF, Liao PL, Huang JY, Chan MY, Yeh CB. Association of Thiazide Use in Patients with Hypertension with Overall Fracture Risk: A Population-Based Cohort Study. J Clin Med. 2022;11(12):3304. doi: 10.3390/jcm11123304.
- Kaushal N, Vohora D, Jalali RK, Jha S. Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population – a cross-sectional retrospective study. Osteoporos Sarcopenia. 2018;4(2):53–60.
- Mykhailovska NS, Stetsiuk IO, Kulynych TO, Gorbachova SV, Zhulkevych IV. The interrelationship of bone and cardiovascular remodeling biomarkers and clinical peculiarities of coronary artery disease in postmenopausal women. Reumatologia. 2020;58(3):142–149. doi: 10.5114/reum.2020.96687.
- Rapoport RM, Soleimani M. Mechanism of Thiazide Diuretic Arterial Pressure Reduction: The Search Continues . Front. Pharmacol. 2019. doi.org/10.3389/fphar.2019.00815
- Trujillo H, Caravaca-Fontán F, Caro J, Morales E, Praga M. The Forgotten Antiproteinuric Properties of Diuretics. Am J Nephrol. 2021; 52:435–449. doi.org/10.1159/000517020
- Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, Liu S, Looker AC, Wallace TC, Wang D.D. Calcium plus vitamin D supplementation and risk of fractures: An updated meta-analysis from the National Osteoporosis Foundation. Osteoporos. Int. 2016; 27:367–376. doi: 10.1007/s00198-015-3386-5.
- Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD001841. DOI: 10.1002/14651858.CD001841.pub3
- Ye Z, Lu H, Liu P. Association between essential hypertension and bone mineral density: a systematic review and meta-analysis. Oncotarget. 2017;8(40):68916–68927. doi: 10.18632/oncotarget.20325. PMID: 28978167; PMCID: PMC5620307.
- Zhao Z, Zhang Y, Wang C. et al. Angiotensin II upregulates RANKL/NFATC1 expression in synovial cells from patients with rheumatoid arthritis through the ERK1/2 and JNK pathways. J Orthop Surg Res. 2021:16: 297. doi.org/10.1186/s13018-021-02451-0
- Zhdan VM, Kitura YEM, Kitura OYE, Babanina MYU, Tkachenko MV. Clinical Approaches to Therapy of Arterial Hypertension in Women’s Postmenopaceus. Family Medicine, 2019 (2), 76–79. https://doi.org/10.30841/2307-5112.2.2019.175177
- Zhuoqing H, Kevin Y, Zhihui H, Miaosheng L, Hao W, Zheng T, Baitong C, Chengbiao S, De C, Jinrong X.. Determining the association between hypertension and bone metabolism markers in osteoporotic patients. Medicine. 2021; 100(24): e26276. doi: 10.1097/MD.0000000000026276.
|
| Publication of the article |
«World of Medicine and Biology» №4(82), 2022 year, 026-031 pages, index UDK 616.12-008.331.1+616.71-007.234]:616.13-07 |
| DOI |
10.26724/2079-8334-2022-4-82-26-31 |
